Abstract
Objective Postpartum depression (PPD) represents a major contributor to postpartum morbidity and mortality. Beyond efforts at routine screening, risk stratification models could enable more targeted interventions in settings with limited resources. Thus, we aimed to develop and estimate the performance of a generalizable risk stratification model for PPD in patients without a history of depression using information collected as part of routine clinical care.
Methods We performed a retrospective cohort study of all individuals who delivered between 2017 and 2022 in one of two large academic medical centers and six community hospitals. An elastic net model was constructed and externally validated to predict PPD using sociodemographic factors, medical history, and prenatal depression screening information, all of which was known before discharge from the delivery hospitalization.
Results The cohort included 29,168 individuals; 2,703 (9.3%) met at least one criterion for postpartum depression in the 6 months following delivery. In the external validation data, the model had good discrimination and remained well-calibrated: area under the receiver operating characteristic curve 0.721 (95% CI: 0.707-0.734), Brier calibration score 0.088 (95% CI: 0.084 – 0.092). At a specificity of 90%, the positive predictive value was 28.0% (95% CI: 26.0-30.1%), and the negative predictive value was 92.2% (95% CI: 91.8-92.7%).
Conclusions These findings demonstrate that a simple machine-learning model can be used to stratify the risk for PPD before delivery hospitalization discharge. This tool could help identify patients within a practice at the highest risk and facilitate individualized postpartum care planning regarding the prevention of, screening for, and management of PPD at the start of the postpartum period and potentially the onset of symptoms.
Competing Interest Statement
Dr. Clapp serves on the scientific advisory board member and has holds equity in Delfina Care. Dr. Perlis has received consulting fees from Burrage Capital, Genomind, Belle Artificial Intelligence, and Takeda. He holds equity in Psy Therapeutics, Belle Artificial Intelligence, and Circular Genomics. Dr. Edlow has received consulting fees from Mirvie, Inc. and research funding from Merck Pharmaceuticals, both outside of the work reported here. The other authors report no disclosures.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Mass General Brigham gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures: Dr. Clapp serves on the scientific advisory board member and has holds equity in Delfina Care. Dr. Perlis has received consulting fees from Burrage Capital, Genomind, Belle Artificial Intelligence, and Takeda. He holds equity in Psy Therapeutics, Belle Artificial Intelligence, and Circular Genomics. Dr. Edlow has received consulting fees from Mirvie, Inc. and research funding from Merck Pharmaceuticals, both outside of the work reported here. The other authors report no disclosures.
Prior presentation: n/a
Data Availability
Data used in this study has not been made publicly available.
